NASDAQ:CLVS - Clovis Oncology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.90 -0.46 (-7.23 %) (As of 04/1/2020 01:27 PM ET) Add Compare Today's Range$5.81Now: $5.90▼$6.4450-Day Range$3.77MA: $7.29▼$11.0052-Week Range$2.93Now: $5.90▼$25.88Volume2.67 million shsAverage Volume7.47 million shsMarket Capitalization$433.36 millionP/E RatioN/ADividend YieldN/ABeta3.12 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CLVS Previous Symbol CUSIP18946410 CIK1466301 Webhttp://www.clovisoncology.com/ Phone303-625-5000Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.55Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$143.01 million Price / Sales3.03 Cash FlowN/A Price / Cash FlowN/A Book Value($3.17) per share Price / Book-1.86Profitability EPS (Most Recent Fiscal Year)($7.60) Net Income$-400,420,000.00 Net Margins-280.01% Return on Equity-1,576.32% Return on Assets-57.33%Miscellaneous EmployeesN/A Outstanding Shares73,450,000Market Cap$433.36 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive CLVS News and Ratings via Email Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:CLVS Rates by TradingView Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions How has Clovis Oncology's stock been impacted by COVID-19 (Coronavirus)? Clovis Oncology's stock was trading at $6.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLVS stock has decreased by 4.4% and is now trading at $5.90. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Clovis Oncology? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Clovis Oncology. When is Clovis Oncology's next earnings date? Clovis Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Clovis Oncology. How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) released its quarterly earnings data on Monday, February, 24th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.71) by $0.10. The biopharmaceutical company earned $39.31 million during the quarter, compared to analyst estimates of $38.79 million. Clovis Oncology had a negative net margin of 280.01% and a negative return on equity of 1,576.32%. View Clovis Oncology's earnings history. What guidance has Clovis Oncology issued on next quarter's earnings? Clovis Oncology updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $38.3-39.3 million, compared to the consensus revenue estimate of $40.39 million. What price target have analysts set for CLVS? 14 equities research analysts have issued 12-month price objectives for Clovis Oncology's stock. Their forecasts range from $4.00 to $36.00. On average, they anticipate Clovis Oncology's stock price to reach $20.90 in the next twelve months. This suggests a possible upside of 254.2% from the stock's current price. View analysts' price targets for Clovis Oncology. What are Wall Street analysts saying about Clovis Oncology stock? Here are some recent quotes from research analysts about Clovis Oncology stock: 1. According to Zacks Investment Research, "Clovis reported impressive third-quarter results with earnings and revenues beating estimates. Market share of Clovis’ Rubraca in the ovarian cancer PARP inhibitor market improved in the first half. Approval in second-line maintenance setting for ovarian cancer irrespective of the BRCA-mutation is a positive. Successful development of Rubraca in several ongoing studies, targeting different types of ovarian cancer patients, is likely to boost the drug’s prospects. The company is actively working on expanding the label of Rubraca as monotherapy or combination therapy in and beyond ovarian cancer. However, Rubraca faces strong competition from other PARP inhibitors in the market, Lynparza and Zejula. Moreover, competition is likely to increase with several others under development." (11/27/2019) 2. HC Wainwright analysts commented, "Our $36 price target is derived from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for Rubraca in ovarian cancer combination and prostate cancer indications, and the net present value (NPV) for the current commercial business." (7/3/2019) Has Clovis Oncology been receiving favorable news coverage? Media headlines about CLVS stock have trended very positive recently, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Clovis Oncology earned a news impact score of 4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent press coverage is very unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutClovis Oncology. Who are some of Clovis Oncology's key competitors? Some companies that are related to Clovis Oncology include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Micron Technology (MU), Amarin (AMRN), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Advanced Micro Devices (AMD), NVIDIA (NVDA), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). Who are Clovis Oncology's key executives? Clovis Oncology's management team includes the following people: Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51) What is Clovis Oncology's stock symbol? Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS." How do I buy shares of Clovis Oncology? Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Clovis Oncology's stock price today? One share of CLVS stock can currently be purchased for approximately $5.90. How big of a company is Clovis Oncology? Clovis Oncology has a market capitalization of $433.36 million and generates $143.01 million in revenue each year. The biopharmaceutical company earns $-400,420,000.00 in net income (profit) each year or ($7.60) on an earnings per share basis. View additional information about Clovis Oncology. What is Clovis Oncology's official website? The official website for Clovis Oncology is http://www.clovisoncology.com/. How can I contact Clovis Oncology? Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected] MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 558 (Vote Outperform)Underperform Votes: 542 (Vote Underperform)Total Votes: 1,100MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/1/2020 by MarketBeat.com StaffFeatured Article: What are defining characteristics of a correction?
